{
    "id": 7248,
    "cites": 9,
    "cited_by": 2,
    "reference": [
        "3240-3244. Cookson, Clive, Essential Engineering: How Different Is Biotechnology'DONE', Financial Times, April 25,",
        "1995, p. 10. GenBank, Release 65.0, machine readable data base, Palo Alto, CA: IntelliGentics, Inc., September",
        "79: 957-970. Jaffe, Adam B., Manuel Trajtenberg, and Rebecca Henderson, Geographic Localization of Knowledge",
        "33 Spillovers as Evidenced by Patent Citations, Quarterly Journal of Economics, August 1993,",
        "35 Zucker, Lynne G., and Michael R. Darby, Present at the Biotechnological Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm, Research Policy, December",
        "5. As quoted in Clive Cookson (1995). Cookson reports that [t]oday, genetic engineering is used daily as a laboratory tool by every research-based pharmaceutical and biotech company.",
        "17. Zucker, Darby, and Armstrong (1998) present some evidence that entrants may be more successful in biotech research than incumbents.",
        "20. Zucker, Darby, and Brewer (1998) report that both stars and collaborators have positive effects in the corresponding model for the U.S. Differences between the U.S. and Japan will be explored in Section VI below. Note, however, that in long-run poisson regressions (not feasible here because of the smaller number of prefectures than U.S. BEAs) Zucker, Darby, and Brewer (1998) do find some evidence of negative effects of the number of active collaborators.",
        "21. The two broader definitions (b) and (c) were based on Dodwell Marketing Consultants Industrial Groupings in Japan. The narrower definitions (a) and (d) were based on Keizai Chosa Kyokais Keiretsu no Kenkyu (KNK). (Weinstein and Yishay Yafeh 1995, p. 367.)"
    ]
}